12
views
0
recommends
+1 Recommend
2 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Novel SLCO2A1 mutations cause gender-differentiated pachydermoperiostosis

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Primary hypertrophic osteoarthropathy (PHO) is a rare familial disorder with reduced penetrance for females. The genetic mutations associated with PHO have been identified in HPGD and SLCO2A1, which involved in prostaglandin E2 metabolism. Here, we report 5 PHO patients from four non-consanguineous families. Two heterozygous mutations in solute carrier organic anion transporter family member 2A1 ( SLCO2A1) were identified in two brothers by whole-exome sequencing. Three heterozygous mutations and one homozygous mutation were identified in other three PHO families by Sanger sequencing. However, there was no mutation in HPGD. These findings confirmed that homozygous or compound heterozygous mutations of SLCO2A1 were the pathogenic cause of PHO. A female individual shared the same mutations in SLCO2A1 with her PHO brother but did not have any typical PHO symptoms. The influence of sex hormones on the pathogenesis of PHO and its implication were discussed.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: not found
          • Article: not found

          Puberty and structural brain development in humans

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy.

            Digital clubbing, recognized by Hippocrates in the fifth century BC, is the outward hallmark of pulmonary hypertrophic osteoarthropathy, a clinical constellation that develops secondary to various acquired diseases, especially intrathoracic neoplasm. The pathogenesis of clubbing and hypertrophic osteoarthropathy has hitherto been poorly understood, but a clinically indistinguishable primary (idiopathic) form of hypertrophic osteoarthropathy (PHO) is recognized. This familial disorder can cause diagnostic confusion, as well as significant disability. By autozygosity methods, we mapped PHO to chromosome 4q33-q34 and identified mutations in HPGD, encoding 15-hydroxyprostaglandin dehydrogenase, the main enzyme of prostaglandin degradation. Homozygous individuals develop PHO secondary to chronically elevated prostaglandin E(2) levels. Heterozygous relatives also show milder biochemical and clinical manifestations. These findings not only suggest therapies for PHO, but also imply that clubbing secondary to other pathologies may be prostaglandin mediated. Testing for HPGD mutations and biochemical testing for HPGD deficiency in patients with unexplained clubbing might help to obviate extensive searches for occult pathology.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy.

              By using whole-exome sequencing, we identified a homozygous guanine-to-adenine transition at the invariant -1 position of the acceptor site of intron 1 (c.97-1G>A) in solute carrier organic anion transporter family member 2A1 (SLCO2A1), which encodes a prostaglandin transporter protein, as the causative mutation in a single individual with primary hypertrophic osteoarthropathy (PHO) from a consanguineous family. In two other affected individuals with PHO from two unrelated nonconsanguineous families, we identified two different compound heterozygous mutations by using Sanger sequencing. These findings confirm that SLCO2A1 mutations inactivate prostaglandin E(2) (PGE(2)) transport, and they indicate that mutations in SLCO2A1 are the pathogenic cause of PHO. Moreover, this study might also help to explain the cause of secondary hypertrophic osteoarthropathy.
                Bookmark

                Author and article information

                Journal
                Endocr Connect
                Endocr Connect
                EC
                Endocrine Connections
                Bioscientifica Ltd (Bristol )
                2049-3614
                November 2018
                30 August 2018
                : 7
                : 11
                : 1116-1128
                Affiliations
                [1 ]Department of Biochemistry and Molecular Biology Center for DNA Typing, Air Force Medical University, Xi’an, Shaanxi, People’s Republic of China
                [2 ]Department of General Surgery Tangdu Hospital, Air Force Medical University, Xi’an, Shaanxi, People’s Republic of China
                [3 ]Department of Microbiology Air Force Medical University, Xi’an, Shaanxi, People’s Republic of China
                [4 ]Department of Biochemistry and Molecular Biology Air Force Medical University, Xi’an, Shaanxi, People’s Republic of China
                Author notes
                Correspondence should be addressed to Y Wu or L Wang: wuym@ 123456fmmu.edu.cn or lfwang@ 123456fmmu.edu.cn

                *(L Yuan, X Chen and Z Liu contributed equally to this work)

                Article
                EC180326
                10.1530/EC-18-0326
                6223238
                30352415
                5ac95e82-f3d2-4f94-9917-2ae2bd2137a9
                © 2018 The authors

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                : 10 August 2018
                : 30 August 2018
                Categories
                Research

                primary hypertrophic osteoarthropathy,exome sequencing,solute carrier organic anion transporter family member 2a1,female atypical phenotype,hormone therapeutics

                Comments

                Comment on this article